

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Fernando Rubio	01/18/2013
RECEIVING PARTY DATA	
Name:	Abraxis LLC
Street Address:	54 Steam Whistle Drive
City:	Warminster
State/Country:	PENNSYLVANIA
Postal Code:	18974
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13585097
CORRESPONDENCE DATA	
Fax Number:	6106882572
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	610-724-2952
Email:	afried@afpatlaw.com
Correspondent Name:	Allan Fried
Address Line 1:	150 N. Radnor Chester Road
Address Line 2:	Suite F-200
Address Line 4:	Radnor, PENNSYLVANIA 19087
ATTORNEY DOCKET NUMBER:	ABX-0024
NAME OF SUBMITTER:	Allan Fried
Total Attachments: 2 source=Fernando Rubio Assignment#page1.tif source=Fernando Rubio Assignment#page2.tif	

CH \$40.00 13585097

## ASSIGNMENT OF PATENT APPLICATION

This Agreement, whose effective date is the later of the Signature Dates below, is between Fernando Rubio ("Assignor"), residing at 45 Mystic View Lane, Doylestown, PA 18901 and Abraxis, L.L.C. ("Company") which has its principal office located at 54 Steam Whistle Drive, Warminster, PA 18974.

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, assigns and transfers to Company, Assignor's entire right, title and interest, in (1) any and all invention(s) which are disclosed in the following Patent Application filed at the United States Patent and Trademark Office:

Title: Antibodies and Assays for beta-N-methylamino-L-alanine

Patent Application No.: 13/585,097

Filed: August 14, 2012

Attorney Docket No.: ABX-0024

and (2) any future improvements thereon which Assignor makes or conceives during the course of Assignor's association with Company.

Assignor also hereby sells, assigns, and transfers to Company, Assignor's entire right, title and interest in future patent applications that disclose the Invention set forth in Application 13/585,097 or disclose a modified version of said Invention, said future applications including but not limited to U.S. or foreign applications that claim, as regards the Invention, the benefit of the filing date of said Application or a right of priority based upon said Application. Examples of such future applications include but are not limited to: United States divisional, continuation, continuation-in-part applications, and reissue applications, an International PCT application, national or regional phase applications that emanate from an International PCT application that claims priority to said Patent, and any non-PCT application filed in a foreign country or regional patent office.

Assignor further agrees that: (1) Company may file any of the aforementioned non-provisional patent applications for a patent in its own name where permitted by the law of the


country where filed, and (2) when requested, Assignor will execute without charge, but at Company's expense, all rightful declarations, oaths, assignments, powers of attorney and other papers, needed to prosecute said patent applications.


Assignor attests that no assignment, license or other agreement affecting the rights, title and interest referred to above has been, or will be, conveyed by Assignor to an entity other than Company.

Company accepts all present and future assignments referred to above.

IN WITNESS THEREOF, having read the aforesaid assignment agreement and intending to be legally bound thereby, Company and Assignor execute this agreement and agree to its terms.

The Assignor, on behalf of himself:


  
Name: **Fernando Rubio**


  
Signature Date

  
Witness to Fernando Rubio's Signature


  
Signature Date

On behalf of the Company:

  
Officer's Name: **Fernando Rubio**  
Title: **President of Abraxis, L.L.C.**

  
Signature Date

  
Witness to Fernando Rubio's Signature

  
Signature Date